Jinyu Bio-technology Co., Ltd. (SHA:600201)
11.67
-0.44 (-3.63%)
May 29, 2026, 3:00 PM CST
Jinyu Bio-technology Revenue
Jinyu Bio-technology had revenue of 346.46M CNY in the quarter ending March 31, 2026, a decrease of -1.45%. This brings the company's revenue in the last twelve months to 1.39B, up 10.50% year-over-year. In the year 2025, Jinyu Bio-technology had annual revenue of 1.40B with 11.23% growth.
Revenue (ttm)
1.39B
Revenue Growth
+10.50%
P/S Ratio
9.17
Revenue / Employee
739.66K
Employees
1,881
Market Cap
12.75B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.40B | 140.96M | 11.23% |
| Dec 31, 2024 | 1.26B | -342.77M | -21.45% |
| Dec 31, 2023 | 1.60B | 69.56M | 4.55% |
| Dec 31, 2022 | 1.53B | -247.65M | -13.94% |
| Dec 31, 2021 | 1.78B | 194.41M | 12.29% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Chengzhi | 10.87B |
| Pacific Shuanglin Bio-pharmacy | 2.60B |
| Anhui Anke Biotechnology (Group) | 2.56B |
| Tibet Cheezheng Tibetan Medicine | 2.42B |
| Inner Mongolia Furui Medical Science | 1.63B |
| Hualan Biological Vaccine | 1.20B |
| Chengdu Olymvax Biopharmaceuticals | 774.47M |
| Mabwell (Shanghai) Bioscience | 745.32M |